Daewoong withdraws its Herceptin biosimilar Ogivri from mkt
By Lee, Hye-Kyung | translator Kim, Jung-Ju
23.09.05 12:03:24
가나다라
0
Withdraws its license in Korea due to lack of performance after receiving marketing authorization in Korea in 2020
Is considering whether to start its own CDMO business rather than selling biosimilars imported from other companies
▲Pic of Ogivri sold in the U.S.
‘Ogivri Inj. 150mg (trastuzumab),’ the third Herceptin biosimilar to be approved in Korea, is withdrawing from the Korean market.The Ministry of Food and Drug Safety announced on the 4th that Daewoong Pharmaceutical voluntarily withdrew its license for Ogivri in Korea.
Ogivri was developed by the Indian pharmaceutical company Biocon. Alvogen Korea received domestic approval for the product on August 25, 2020, and the license holder was later changed to Daewoong Pharmaceutical.
The company received insurance reimbursement for the drug on November 1, 2020, in preparation for releasing Ogivri.
However, referring to its non-ex
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)